GRIPHON Trial—The First Long-term Outcomes Trial Targeting the Prostacyclin Pathway (median duration of exposure 1.4 years)1,2

GRIPHON IS THE LARGEST OUTCOMES TRIAL EVER CONDUCTED IN PAH (N=1156)

Study description: multicenter, long-term, double-blind, placebo-controlled, parallel-group, event-driven phase 3 study in patients (UPTRAVI: n=574; placebo: n=582) with symptomatic PAH (nearly all WHO FC II-III at baseline). The exposure to UPTRAVI in this trial was up to 4.2 years.


ALL PATIENTS COMPLETED THEIR TITRATION WITHIN THE FIRST 12 WEEKS

GRIPHON Trial Duration of Exposure on UPTRAVI Results